

Masaryk University

Faculty

Faculty of Medicine

Procedure field

Oncology

Applicant

MUDr. Peter Múdry, Ph.D.

Applicant's home unit, institution

Faculty of Medicine, Masaryk University

Habilitation thesis

Novel strategies in diagnostics and therapy in pediatric oncology

Board members

Chair

prof. MUDr. Pavel Šlampa, CSc.

Faculty of Medicine, Masaryk University

Members

Prof Michael Brada

Faculty of Health and Life Sciences, University of Liverpool

prof. MUDr. Hana Hrstková, CSc.

MU - Faculty of Medicine

prof. MUDr. Jiří Petera, Ph.D.

Klinika onkologie a radioterapie LF UK a FN Hradec Králové

doc. MUDr. Lucie Šrámková, Ph.D.

Klinika dětské hematologie a onkologie 2. LF UK a FN Motol

Evaluation of the applicant's scholarly/artistic qualifications

Peter Múdry, MD, Ph.D., graduated the Faculty of Medicine of Masaryk University in Brno, Czech Republic (study program: General Medicine) in 1998. After his graduation, he started the career at the Department of Biology Faculty of Medicine of Masaryk University as lecturer and PhD student. A half year later he has began working as fellow at Department of Pediatric Oncology at University Hospital Brno and Masaryk University where he has continued his further postgraduate education. His current position is senior consultant and clinical director of this department. He successfully completed her specialization in Pediatrics I.st degree (2001) and Medical oncology (2005). In 2009 he successfully defended her doctoral thesis focusing on the Mannose binding lectin in children with malignancy and obtained the PhD title. Dr. Mudry has an impressive publication record of 54 peer-reviewed articles listed in the NIH National Library of Medicine (PubMed) and more two articles in another peer-reviewed journals. Among his rather rich publishing activities, he is the first or corresponding author of 11 articles published in impacted journals. He is the author of the four chapters in scholarly book publications. His research carrier is supported by 779 citations in WoS (excluding self-citations) and H-index 15. Dr.Múdry was clinical lead of innovative project of dendritic cell vaccine in high risk pediatric oncology patients which was conducted on Masaryk University, which resulted to prolonged survival of these patients The collaboration of Dr.Múdry within European Soft Tissue Sarcoma study Group has major impact on setting a new treatment standards on the field as marked by co-authorship in published papers (Bisogno et al, Lancet Oncology 2019, Orbach et al, Eur.J .Cancer 2016, Galego et al.Cancer 2018, Bisogno et al. J. Clin.Oncol. 2023 etc). From aforementioned, it is clear that Dr. Múdry is experienced researcher with evidenced impact on science in the field of Pediatric Oncology.

Conclusion: The applicant's scholarly/artistic capabilities **meet** the requirements expected of applicants participating in a habilitation appointment procedure in the field of Oncology.

Evaluation of the applicant's pedagogical experience

Peter Múdry, MD, Ph.D., has started his teaching activity in 1998 as lecturer at Department of Biology, Faculty of Medicine, Masaryk University. He regularly teaches master class exercises at Department of Pediatric Oncology University Hospital Brno and Masaryk University both in Czech and English. He successfully supervised 1 Master's thesis. In addition, his teaching activity is supported by chapters in 4 comprehensive textbooks. He is currently supervisor of one doctoral candidate.

Conclusion: The applicant's pedagogical capabilities **meet** the requirements expected of applicants participating in a habilitation appointment procedure in the field of Oncology.

Habilitation thesis evaluation

The habilitation thesis is divided into three parts. The first one focuses on innovative treatment in paediatric oncology. Dr.Múdry demonstrates in his publications the scientific contribution to the field. His first-authored paper on successful HPV vaccination in a patient with recurrent laryngeal papillomatosis is mentioned in the citations as one of the first to use this method. The main contribution of innovative approaches can be seen in the research on the use of dendritic cell vaccine in high-risk pediatric patients who have a low chance of survival using conventional treatment methods. The published data demonstrate a prolonged chance of survival in these patients while maintaining a very good quality of life. It should be emphasised that this is a treatment combined with metronomic low-dose chemotherapy. In the second part, Dr. Múdry discusses research on antifungal therapy in haemato-oncologically immunocompromised patients. An important contribution is the collaboration of this issue within the national CELL group, documented by publications. The third part describes the treatment of childhood sarcomas. As Dr. Múdry documents in the publication activity, this is the most extensive part of his focus. The cooperation of sarcoma treatment within Masaryk University and other national and international centres leads to standardisation of care and adequate best possible treatment results, as documented by the examples of osteosarcoma, rhabdomyosarcoma and infantile fibrosarcoma treatment. The habilitation thesis

was reviewed by three respected experts in the oncology. All reviewers agreed that the habilitation thesis of Dr. Múdry presents new knowledge in the Pediatric Oncology

Conclusion: The applicant's habilitation thesis **meets** the requirements expected of habilitation theses in the field of Oncology.

Habilitation Board Decision on the Nomination for Appointment to Associate Professor

Secret vote results

Voting took place: electronically

Number of board members	5
Number of votes cast	5
of which	5
in favour	5
against	0

Board decision

Based on the outcome of the secret vote and following an evaluation of the applicant's scholarly or artistic qualifications, pedagogical experience and habilitation thesis, the board hereby submits a proposal to the Scientific Board of the Faculty of Medicine of Masaryk University to **appoint the applicant associate professor** of Oncology.

In Brno on 30.04.2025

prof. MUDr. Pavel Šlampa, CSc.

.....